Previous 10 | Next 10 |
home / stock / bovnf / bovnf news
BioInvent International press release ( OTCPK:BOVNF ): Q2 GAAP EPS of SEK 2.86. Revenue of SEK 270.9M (+5011.3% Y/Y). Cash flow from operating activities -SEK62.5M vs. -SEK63.1M Y/Y. For further details see: BioInvent International GAAP EPS of...
BioInvent International press release (OTC:BOVNF): Q1 GAAP EPS of -SEK 1.16. Revenue of SEK 16.7M (+169.4% Y/Y). Cash flow from operating activities SEK -79.8M. Liquid funds, current and long-term investments as of March 31, 2022: SEK 1,280.9M. For further details see: BioInvent Interna...
BioInvent International (OTC:BOVNF) announced that the medical product regulators in China have approved a Clinical Trial Application (CTA) submitted by CASI Pharmaceuticals (NASDAQ:CASI) to begin two clinical trials for the company’s lead asset, BI-1206 in non-Hodgkin's Lymphoma (NHL)...
BioInvent International AB (BOVNF) and Transgene (TRGNF) announce that their Investigational New Drug ((IND)) application for BT-001 has been granted by the FDA.This IND will allow patients in U.S. to be enrolled into ongoing Phase 1/2a clinical trial of BT-001, which is evaluating BT-001 as ...
Resolutions at BioInvent's Annual General Meeting 2021 PR Newswire LUND, Sweden , April 29, 2021 /PRNewswire/ -- The Annual General Meeting ("AGM") of BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) resolved to elect Vincent Ossipow as new...
BioInvent's partner Oncurious NV presents Phase I data on TB-403 in pediatric cancer PR Newswire LUND, Sweden , April 12, 2021 /PRNewswire/ -- BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) today announced that Oncurious NV has presented data f...
BioInvent International's Annual Report 2020 published PR Newswire LUND, Sweden , April 8, 2021 /PRNewswire/ -- BioInvent International AB (publ) (Nasdaq Stockholm: BINV) today announced that the Annual Report for 2020 is published and available at the company's ...
Change in the number of shares and votes in BioInvent International AB PR Newswire LUND, Sweden , March 31, 2021 /PRNewswire/ -- BioInvent International AB (publ) (Nasdaq Stockholm: BINV) today announced that the company's total number of shares as per March 31...
BioInvent presents proof-of-concept data on anti-FcyRIIB antibody BI-1607 at AACR Annual Meeting 2021 - BI-1607 designed to boost efficacy and overcome patients' resistance to clinically validated antibody therapy PR Newswire LUND, Sweden , March 11, 2021 /PR...
BioInvent International AB (BOVNF) and Transgene (TRGNF) have enrolled the first patient in a Phase I/IIa clinical trial evaluating BT-001 as a single agent and in combination with pembrolizumab (anti-PD-1 treatment). The Phase I will be divided into two parts:Part A will enrol...
News, Short Squeeze, Breakout and More Instantly...
Model-informed approach supporting dose selection and optimization of clinical development Confirming wide potential dose-range of BI-1808 in the continued clinical evaluation which already has shown promising single agent safety and efficacy Poster to be presented at PAGE 2024 to be ...
LUND, SWEDEN / ACCESSWIRE / June 24, 2024 / BioInvent International AB ("BioInvent") (STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that the China Nat...
BioInvent International (STO:BINV) Discussion on TNFR2 and FcyRIIB as promising targets in immuno-oncology on June 18, 2024 LUND, SWEDEN / ACCESSWIRE / May 30, 2024 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development...